4//SEC Filing
TETLOW SHARON 4
Accession 0001235802-09-000107
CIK 0000865231other
Filed
Oct 14, 8:00 PM ET
Accepted
Oct 15, 4:43 PM ET
Size
25.0 KB
Accession
0001235802-09-000107
Insider Transaction Report
Form 4
CELL GENESYS INCcege
TETLOW SHARON
SVP & CFO
Transactions
- Disposition to Issuer
Employee Stock Option (right to buy)
2009-10-14−1,250→ 0 totalExercise: $6.07Exp: 2016-02-07→ common stock (1,250 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2009-10-14−28,750→ 0 totalExercise: $6.07Exp: 2016-02-07→ common stock (28,750 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2009-10-14−49,998→ 0 totalExercise: $1.84Exp: 2018-02-06→ common stock (49,998 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2009-10-14−68,964→ 0 totalExercise: $5.80Exp: 2015-06-01→ common stock (68,964 underlying) - Disposition to Issuer
Common Stock
2009-10-14−18,449→ 0 total - Disposition to Issuer
Employee Stock Option (right to buy)
2009-10-14−81,036→ 0 totalExercise: $5.80Exp: 2015-06-01→ common stock (81,036 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2009-10-14−50,002→ 0 totalExercise: $1.84Exp: 2018-02-06→ common stock (50,002 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2009-10-14−36,459→ 0 totalExercise: $3.07Exp: 2017-02-07→ common stock (36,459 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2009-10-14−13,541→ 0 totalExercise: $3.07Exp: 2017-02-07→ common stock (13,541 underlying)
Footnotes (13)
- [F1]Pursuant to the merger of Cell Genesys, Inc. with and into BioSante Pharmaceuticals, Inc. (the "Merger"), such shares were disposed of in exchange for 3,372 shares of BioSante common stock having a market value of $1.82 per share on the effective date of the Merger.
- [F10]Pursuant to the Merger, this option was assumed by BioSante in the Merger and replaced with an option to purchase 5,255 shares of BioSante common stock for an exercise price of $33.21 per share.
- [F11]Options granted on June 1, 2005. Twenty-five percent (25%) of the option veted on June 1, 2006 and the remainder vests upon the optionee's completion of each additional month of service in a series of thirty-six (36) successive equal monthly installments.
- [F12]Pursuant to the Merger, this option was assumed by BioSante in the Merger and replaced with an option to purchase 12,606 shares of BioSante common stock for an exercise price of $31.73 per share.
- [F13]Pursuant to the Merger, this option was assumed by BioSante in the Merger and replaced with an option to purchase 14,813 shares of BioSante common stock for an exercise price of $31.73 per share.
- [F2]Option granted on February 6, 2008. Vesting occurs over a period of four years in a series of forty-eight (48) successive, equal monthly installments beginning on the grant date.
- [F3]Pursuant to the Merger, this option was assumed by BioSante in the Merger and replaced with an option to purchase 9,139 shares of BioSante common stock for an exercise price of $10.07 per share.
- [F4]Pursuant to the Merger, this option was assumed by BioSante in the Merger and replaced with an option to purchase 9,140 shares of BioSante common stock for an exercise price of $10.07 per share.
- [F5]Options granted on February 7, 2007. Vesting occurs over a period of four years in a series of forty-eight (48) successive, equal monthly installments beginning on the grant date.
- [F6]Pursuant to the Merger, this option was assumed by BioSante in the Merger and replaced with an option to purchase 6,664 shares of BioSante common stock for an exercise price of $16.80 per share.
- [F7]Pursuant to the Merger, this option was assumed by BioSante in the Merger and replaced with an option to purchase 2,475 shares of BioSante common stock for an exercise price of $16.80 per share.
- [F8]Options granted on February 7, 2006. Vesting occurs over a period of four years in a series of forty-eight (48) successive, equal monthly installments beginning on the grant date.
- [F9]Pursuant to the Merger, this option was assumed by BioSante in the Merger and replaced with an option to purchase 228 shares of BioSante common stock for an exercise price of $33.21per share.
Documents
Issuer
CELL GENESYS INC
CIK 0000865231
Entity typeother
Related Parties
1- filerCIK 0001328565
Filing Metadata
- Form type
- 4
- Filed
- Oct 14, 8:00 PM ET
- Accepted
- Oct 15, 4:43 PM ET
- Size
- 25.0 KB